Clinical Trial Update: Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating MMH-MAP for mild cognitive impairment following ischemic stroke has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment
• Stroke

Drugs mentioned

• MMH-MAP

Snippet

Sponsor: Materia Medica Holding | Conditions: Mild Cognitive Impairment, Ischemic Stroke | Phase 3 | Status: COMPLETED | Results posted: 2021-02-23